Sanity Group Becomes Part of Canadian Cannabis Market Leader Organigram Global to Drive International Growth

The strategic partnership strengthens the companies’ joint position as emerging players in the global cannabis market, starting from two of the world’s largest medical cannabis markets—Germany and Canada. With its established network of strong partners across the entire value chain, as well as comprehensive regulatory, pharmaceutical and operational expertise, Sanity Group will complement Organigram Global going forward as its European platform with local management in place. No changes to day-to-day operations or the corporate structure are planned at this time.

“Based on our partnership to date, I have great confidence in both companies’ vision to scale internationally,” said Finn Hänsel. “Together we will unlock multifaceted growth opportunities, particularly through entry into new European markets. Organigram has already proven to be an exceptional partner, with deep expertise in cultivation, manufacturing, patient-focused research and innovation. These strengths will be critical in actively shaping the global cannabis market. Our strategic objective is to build a global market leader over the coming years.”

Patient Care, Research and Development as Key Pillars
As part of the proposed transaction, Sanity Group has been valued at a total of up to EUR 250 million, comprising an upfront EUR 130 million and up to EUR 120 million linked to defined performance metrics for  twelve months ending March 31, 2027. Decisions regarding a future governance structure have deliberately not yet been made. “At present, our primary focus is on thoughtful integration and the creation of long-term value, rather than on rapid structural changes,” explained Seyit Kaya, CFO of Sanity Group.

In addition to the continued sourcing of high-quality medical cannabis products, Sanity Group sees significant added value in the merger with Organigram particularly in the areas of research and development for patient care. Through clinical trials of cannabinoid-based medicines and the development of innovative dosage forms, collaboration between the two teams is expected to generate scientifically grounded product innovations for the European medical cannabis market. The Sanity Group shareholders nominated Max Narr, Sanity Group’s former MD and Chief Strategy & Investment Officer, to represent Sanity Group within the Organigram Global board. Max Narr has also been deeply engaged in this transaction as an advisor to the Sanity Group.

From Berlin Startup to European Pioneer
Founded in 2018, Berlin-based Sanity Group is among the best-known and most successful cannabis companies in Europe. Strong revenue growth—from EUR 9 million in 2023 to EUR 60 million in 2025—has secured the company the second-largest market share in Germany. In addition to a diversified brand and product portfolio, deep regulatory expertise and a strong partner network, the company also brings substantial experience in adult-use cannabis research.

As the only German company participating in a scientific pilot project exploring the legal distribution of adult-use cannabis in Switzerland, Sanity Group operates Europe’s first two legal cannabis specialty stores as part of that initiative.

Canadian Market Leader Pursues International Expansion
Organigram, a publicly traded cannabis producer with cultivation, processing and logistics facilities across several Canadian provinces, ranks among the world’s leading specialized cannabis companies. In cooperation with Sanity Group, it is now expanding its international footprint to assume a leading role in Europe. The partners aim to establish patient-centric brands, new product innovations and proven business models across European medical markets, including Germany, Poland, the United Kingdom and Switzerland. Over the longer term, newly emerging legal adult-use markets are also expected to become relevant.

“The future collaboration represents a pivotal step on Organigram’s journey to realize our ambition of becoming a global market leader in the rapidly growing cannabis industry. This transformative transaction brings together two market leaders, immediately expands our commercial presence in Europe and strengthens our competitive position in the world’s largest legal cannabis markets,” said James Yamanaka, CEO of Organigram.

+++

[1] Organigram Global Inc. is listed on both the Nasdaq and the Toronto Stock Exchange under the ticker symbol “OGI”

Members of the media may obtain further detailed information regarding the transaction from Organigram’s public communications.